search
Back to results

Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Primary Purpose

Non Hodgkin Lymphoma

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
JWCAR029
Sponsored by
Peking University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non Hodgkin Lymphoma focused on measuring Non Hodgkin Lymphoma, CD19-targeted chimeric antigen receptor, JWCAR029

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects must meet all of the following criteria to be enrolled in this study:

    1. Age ≥ 18 years at the time of consent
    2. Signed written informed consent obtained prior to any study procedures
    3. Relapsed or refractory B-cell NHL.
    4. PET-positive disease BY Lugano classification
    5. Archived tumor biopsy tissue available from the last relapse and corresponding pathology report available or, if at least one tumor-involved site is deemed accessible at time of screening, willing to undergo pre-treatment biopsy (excisional when possible) for disease confirmation. If a subject has never had a complete response, a sample from the most recent biopsy is acceptable.
    6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    7. Adequate bone marrow, renal, hepatic, pulmonary and cardiac function
    8. Adequate vascular access for leukapheresis procedure
    9. Subjects who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy
    10. Subjects must agree to use appropriate contraception.

Exclusion Criteria:

  • Subjects who meet any of the following criteria will be excluded from participation in this study:

    1. Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study)
    2. History of another primary malignancy that has not been in remission for at least 2 years.
    3. Treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis
    4. Active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection at the time of screening
    5. Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or JWCAR029 administration
    6. Presence of acute or chronic graft-versus-host disease (GVHD)
    7. History of cardiovascular disease
    8. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
    9. Pregnant or nursing women.
    10. Prior CAR T-cell or other genetically-modified T-cell therapy, with the exception of prior JWCAR029 treatment in this protocol for subjects receiving retreatment

Sites / Locations

  • Beijing Cancer Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

JWCAR029

Arm Description

The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 5 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8, 1.5^108 CAR+ T cells.

Outcomes

Primary Outcome Measures

Treatment-related adverse events (AEs)
Physiological parameter
Dose-limiting toxicities of JWCAR029
Physiological parameter
Objective response rate (ORR)
Lugano criteria

Secondary Outcome Measures

Maximum concentration (Cmax) of JWCAR029 in the peripheral blood and bone marrow
Flow cytometry and qPCR
Time to maximum concentration (Tmax) of JWCAR029 in the peripheral blood and bone marrow
Flow cytometry and qPCR
Area-under the concentration-vs-time-curve (AUC) of JWCAR029 in the peripheral blood and bone marrow
Flow cytometry and qPCR
Complete response (CR) rate
Lugano criteria
Duration of response
Lugano criteria
Progression-free survival (PFS) and PFS ratio
Lugano criteria
Overall survival
Physiological parameter
Health-related quality of life (HRQoL)
Questionnaire

Full Information

First Posted
November 10, 2017
Last Updated
July 10, 2019
Sponsor
Peking University
Collaborators
Shanghai Mingju Biotechnology Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03344367
Brief Title
Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Official Title
A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Unknown status
Study Start Date
November 16, 2017 (Actual)
Primary Completion Date
October 2019 (Anticipated)
Study Completion Date
March 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University
Collaborators
Shanghai Mingju Biotechnology Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of autologous CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in adult subjects with relapsed and refractory B-cell Non-Hodgkin lymphoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Hodgkin Lymphoma
Keywords
Non Hodgkin Lymphoma, CD19-targeted chimeric antigen receptor, JWCAR029

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
JWCAR029
Arm Type
Experimental
Arm Description
The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 5 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8, 1.5^108 CAR+ T cells.
Intervention Type
Biological
Intervention Name(s)
JWCAR029
Intervention Description
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
Primary Outcome Measure Information:
Title
Treatment-related adverse events (AEs)
Description
Physiological parameter
Time Frame
2 years
Title
Dose-limiting toxicities of JWCAR029
Description
Physiological parameter
Time Frame
28 days after JWCAR029 infusion
Title
Objective response rate (ORR)
Description
Lugano criteria
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Maximum concentration (Cmax) of JWCAR029 in the peripheral blood and bone marrow
Description
Flow cytometry and qPCR
Time Frame
1 year after JWCAR029 infusion
Title
Time to maximum concentration (Tmax) of JWCAR029 in the peripheral blood and bone marrow
Description
Flow cytometry and qPCR
Time Frame
1 year after JWCAR029 infusion
Title
Area-under the concentration-vs-time-curve (AUC) of JWCAR029 in the peripheral blood and bone marrow
Description
Flow cytometry and qPCR
Time Frame
1 year after JWCAR029 infusion
Title
Complete response (CR) rate
Description
Lugano criteria
Time Frame
2 years
Title
Duration of response
Description
Lugano criteria
Time Frame
2 years
Title
Progression-free survival (PFS) and PFS ratio
Description
Lugano criteria
Time Frame
2 years
Title
Overall survival
Description
Physiological parameter
Time Frame
2 years
Title
Health-related quality of life (HRQoL)
Description
Questionnaire
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects must meet all of the following criteria to be enrolled in this study: Age ≥ 18 years at the time of consent Signed written informed consent obtained prior to any study procedures Relapsed or refractory B-cell NHL. PET-positive disease BY Lugano classification Archived tumor biopsy tissue available from the last relapse and corresponding pathology report available or, if at least one tumor-involved site is deemed accessible at time of screening, willing to undergo pre-treatment biopsy (excisional when possible) for disease confirmation. If a subject has never had a complete response, a sample from the most recent biopsy is acceptable. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Adequate bone marrow, renal, hepatic, pulmonary and cardiac function Adequate vascular access for leukapheresis procedure Subjects who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy Subjects must agree to use appropriate contraception. Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from participation in this study: Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study) History of another primary malignancy that has not been in remission for at least 2 years. Treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis Active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection at the time of screening Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or JWCAR029 administration Presence of acute or chronic graft-versus-host disease (GVHD) History of cardiovascular disease History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis Pregnant or nursing women. Prior CAR T-cell or other genetically-modified T-cell therapy, with the exception of prior JWCAR029 treatment in this protocol for subjects receiving retreatment
Facility Information:
Facility Name
Beijing Cancer Hospital
City
Beijing
ZIP/Postal Code
100142
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34515338
Citation
Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
Results Reference
derived

Learn more about this trial

Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

We'll reach out to this number within 24 hrs